Zacks Investment Research Lowers Aeglea Bio Therapeutics (AGLE) to Hold

Zacks Investment Research lowered shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a buy rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “

Separately, ValuEngine upgraded shares of Aeglea Bio Therapeutics from a hold rating to a buy rating in a report on Saturday, January 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $21.75.

NASDAQ AGLE opened at $8.56 on Tuesday. Aeglea Bio Therapeutics has a one year low of $5.12 and a one year high of $12.00. The company has a market capitalization of $207.03 million, a PE ratio of -4.76 and a beta of 0.86.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.10). Aeglea Bio Therapeutics had a negative return on equity of 62.12% and a negative net margin of 480.92%. As a group, sell-side analysts expect that Aeglea Bio Therapeutics will post -1.86 EPS for the current year.

A number of large investors have recently modified their holdings of AGLE. Orbimed Advisors LLC boosted its position in Aeglea Bio Therapeutics by 26.9% during the 2nd quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company’s stock worth $19,737,000 after acquiring an additional 396,000 shares during the period. Bank of New York Mellon Corp acquired a new position in Aeglea Bio Therapeutics during the second quarter valued at approximately $438,000. Northern Trust Corp boosted its position in Aeglea Bio Therapeutics by 870.0% during the second quarter. Northern Trust Corp now owns 177,184 shares of the biotechnology company’s stock valued at $1,874,000 after purchasing an additional 158,918 shares during the last quarter. Soros Fund Management LLC acquired a new stake in shares of Aeglea Bio Therapeutics in the second quarter valued at approximately $2,184,000. Finally, Renaissance Technologies LLC lifted its position in shares of Aeglea Bio Therapeutics by 417.8% in the second quarter. Renaissance Technologies LLC now owns 528,200 shares of the biotechnology company’s stock valued at $5,588,000 after buying an additional 426,200 shares during the last quarter. 61.13% of the stock is owned by institutional investors.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: Bollinger Bands

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply